US biotech Paragon Therapeutics yesterday revealed that biotech industry veteran Susanna High has been appointed as chief executive (CEO). In this newly-created role, Ms High will lead the team’s continued efforts to propel the development of a pipeline of transformative therapies and accelerate their potential impact. 22 November 2024
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Belgian biotech start-up ExeVir Bio says it has appointed Michael Garrett as its new chief executive (CEO), effective 1 December 2024. 18 November 2024
ALX Oncology Holdings, a Californian immuno-oncology company, has announced the appointment of Alan Sandler as chief medical officer (CMO). 14 November 2024
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
French biotech DiogenX, which is focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announces the appointment of Dr Klara Owen as chief medical officer. 12 November 2024
Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III, as chief executive officer and board director. 11 November 2024
US clinical-stage drug developer Acumen Pharmaceuticals has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief development officer at Acumen. 7 November 2024
Memo Therapeutics, a privately-held Swiss biotech company translating unique responses into superior medicines to treat viral infections and cancer, has appointed a new chief development officer (CDO). 4 November 2024
Netherlands-based Tessellate BIO, a pre-clinical stage biotech with a focus on novel synthetic lethality approaches, today announced the appointment of Dr Lara Boyd as chief business officer. 4 November 2024
Denmark’s Commit Biologics, a specialist in the activation of the complement system to treat cancer and autoimmune disease, has announced the appointment of Mikkel Wandahl Pedersen as chief scientific officer (CSO). 15 October 2024
French biotech Innate Pharma has appointed Jonathan Dickinson as its new chief executive (CEO) and chairman of the executive board, effective November 1, 2024. 14 October 2024
Calluna Pharma, a biotech focused on treating inflammatory and fibrotic diseases, has appointed Mark Gaffney as its new chief executive. 9 October 2024
Privately-held UK biotech Curve Therapeutics has announced the appointment of Rab Prinjha as chief research and development (R&D) officer. 9 October 2024
Ireland and USA-based natural killer (NK) cell therapy biotech ONK Therapeutics has named Bruce McCreedy as chief scientific officer (CSO). 6 December 2022
London-listed Finnish biotech firm Faron Pharmaceuticals today announces the appointment of Faron co-founder Maija Hollmén as chief scientific officer of the company. 1 December 2022
Venture Kick backed Swiss biotech NXI Therapeutics (formerly NextImmune) today announced the appointment of Dr Ruben Herrendorff as its new chief executive (CEO) to drive the next stage of the company’s development. 30 November 2022
French specialty vaccine company Valneva today announced the appointment of Dipal Patel as chief commercial officer (CCO) and management board member. 17 November 2022
Chinese biotech company Hutchmed is evolving its business strategy, targeting a faster path to profitability amid turbulent economic conditions. 15 November 2022
US Biotech Seagen announced that David Epstein has been appointed as a permanent chief executive and board member, replacing interim CEO Roger Dansey. 11 November 2022
After months of searching for a new leader, US biotech major Biogen today announced the appointment of industry veteran Christopher Viehbacher as president and chief executive and a member of its board of directors, effective November 14. 10 November 2022
VectorY Therapeutics, a Dutch biotech developing vectorized antibody approaches for neurodegenerative diseases, has named Sander van Deventer, co-founder and formerly chief technology officer, as chief executive. 8 November 2022
Struggling in the wake of the discontinuation of ziritaxestat, Belgian biotech Galapagos is to undertake a radical restructuring aimed at jump-starting the business. 4 November 2022
Times are tough for cell medicine specialist Rubius Therapeutics, with the firm announcing plans to slash its workforce by 84%, part of a drastic effort to avoid bankruptcy. 3 November 2022
Switzerland-headquartered antibody-drug conjugate specialist ADC Therapeutics today announced the appointment of Kristen Harrington-Smith as chief commercial officer, effective November 17, 2022, and Peter Graham as chief legal officer, effective today. 1 November 2022
Belgian company Rewind Therapeutics, which is developing first-in-class treatments for demyelination-associated diseases, has named Irene Knuesel its new chief scientific officer (CSO). 21 October 2022
After just a year in the role of chief medical officer and head of global clinical development at Californian biotech BioMarin, Harold Bernstein has taken a new job elsewhere. 14 October 2022
Denmark-based clinical-stage firm Evaxion Biotech, which specializes in the development of AI-driven immunotherapies, announced that its new chief executive Per Norlén joined the company on October 3. 12 October 2022
Reports hinting that Michelle McMurry-Heath’s days as president and chief executive of the Biotechnology Innovation Organization (BIO) might be numbered have circulated in recent days. 11 October 2022
Following a board decision to terminate the mandate of Alexis Vandier, France-based biotech OSE Immunotherapeutics (Euronext: OSE) has appointed Dr Nicholas Poirier as its chief executive, with immediate effect. 8 October 2022
T-CURX, a CAR-T cell spin-off from the University of Würzburg, has announced the appointment of its co-founder, Ulf Grawunder, as the chief executive of the company. 6 October 2022